Siemens Healthineers rounds off successful fiscal year 2022 with very good fourth quarter

Fiscal Year 2022 – Strength and resilience in a challenging environment

• First year of “New Ambition” strategy phase successfully completed 
• Comparable revenue growth of 5.9% over the very good prior year; record revenue of around €21.7 billion 
• Revenue increased notably across all segments on a comparable basis: Imaging by 5.8%, Varian by 6.5%, Advanced Therapies by 5.7%, and Diagnostics by 6.6% including around €1.5 billion from rapid COVID-19 antigen tests 
• Equipment book-to-bill ratio outstanding at 1.23 
• Adjusted EBIT rose to almost €3.7 billion – with a good adjusted EBIT margin of 16.8% 
• Adjusted basic earnings per share rose 13% to €2.29 
• Proposed dividend of €0.95 per share (corresponding to a payout ratio of around 52% of net income)

Q4 Fiscal Year 2022 – Very good final quarter with strong development in revenue and earnings

• Strong comparable revenue growth of 6.8% over the very good prior-year period; for the first time, quarterly revenue reached €6.0 billion 
• Revenue increased notably across all four segments on a comparable basis: Imaging by 8.1%, Advanced Therapies by 6.2%, Varian by 5.2%, and Diagnostics by 5.8% including €232 million from rapid COVID-19 antigen tests 
• Continued excellent equipment order intake, equipment book-to-bill ratio of 1.21 
• Adjusted EBIT margin rose to 16.8% 
• Adjusted basic earnings per share rose 22% from the prior-year quarter to €0.65

Outlook for Fiscal Year 2023

For fiscal year 2023, we expect comparable revenue growth of between -1% and 1% compared with fiscal year 2022. Excluding revenue from rapid COVID-19 antigen tests, this corresponds to comparable revenue growth of between 6% and 8%. We expect adjusted basic earnings per share to be between €2.00 and €2.20. 

Bernd Montag, CEO of Siemens Healthineers AG:

“Overall, the Siemens Healthineers team achieved excellent results in the fourth quarter and successfully concluded another fiscal year despite very difficult conditions. It is a sign of strength that in the first year of the ‘New Ambition’ phase of our Strategy 2025, we twice raised and achieved our annual targets for revenue growth and earnings. A continuous increase in order intake strengthens our confidence for the 2023 fiscal year.”